Consonance Capital Management LP Verastem, Inc. Transaction History

Consonance Capital Management LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$2.54 - $4.07 $34.5 Million - $55.4 Million	-13,600,014 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$2.57 - $4.85 $6.16 Million - $11.6 Million	2,398,602 Added 21.41%	13,600,014 $55.4 Million
Q1 2021 May 17, 2021	BUY	$1.9 - $2.82 $6.5 Million - $9.65 Million	3,421,226 Added 43.97%	11,201,412 $27.7 Million
Q4 2020 Feb 16, 2021	BUY	$1.15 - $2.4 $8.95 Million - $18.7 Million	7,780,186 New	7,780,186 $16.6 Million
Q4 2018 Feb 14, 2019	SELL	$3.23 - $7.01 $16.6 Million - $36.1 Million	-5,154,224 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$6.86 - $9.97 $13.8 Million - $20.1 Million	-2,012,442 Reduced 28.08%	5,154,224 $37.4 Million
Q2 2018 Aug 14, 2018	BUY	$2.88 - $8.67 $20.6 Million - $62.1 Million	7,166,666 New	7,166,666 $49.3 Million

297K

Ticker VSTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 210,000,000
Market Cap $832M
Description
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylat...

Get notified when there are updates to the investment portfolio of Consonance Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Consonance Capital Management LP with notifications on news.